A novel population of human melanoma-specific CD8 T cells recognizes melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide

Journal of Immunology

Volumn 179, Issue 11, 2007, Pages 7635-7645

  Derré, Laurent ^a   Ferber, Mathias ^b,c   Touvrey, Cédric ^a   Devevre, Estelle ^a   Zoete, Vincent ^b   Leimgruber, Antoine ^a,b,c   Romero, Pedro ^a   Michielin, Olivier ^a,b,c   Lévy, Frédéric ^a   Speiser, Daniel E ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLALANYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; ALANYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; ALANYLLEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; ALANYLLEUCYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; DECAPEPTIDE; ELONGATION FACTOR TU; EPITOPE; EXOPEPTIDASE; GLUTAMYLALANYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; GLUTAMYLLEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; LEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; MELAN A MART 1; NONAPEPTIDE; SYNTHETIC PEPTIDE; TETRAMER; TUMOR ANTIGEN; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR; MART1 ANTIGEN; PEPTIDE FRAGMENT; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL CLONE; CONTROLLED STUDY; CROSS REACTION; EX VIVO STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; HYDROGEN BOND; MELANOMA; MELANOMA CELL; METASTASIS; MOLECULAR MODEL; MOLECULAR RECOGNITION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; BINDING SITE; CHEMICAL STRUCTURE; IMMUNOLOGY; MOLECULAR CLONING; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; SYNTHESIS; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; BINDING SITES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CLONING, MOLECULAR; HUMANS; IMMUNODOMINANT EPITOPES; MELANOMA; MODELS, MOLECULAR; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, ANTIGEN, T-CELL;

EID: 38849196276     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.11.7635     Document Type: Article

References (48)

1. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190: 705-715.
2. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Lienard, J. C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188: 1641-1650.
3. Benlalam, H., N. Labarriere, B. Linard, L. Derre, E. Diez, M. C. Pandolfino, M. Bonneville, and F. Jotereau. 2001. Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy. Eur. J. Immunol. 31: 2007-2015.
4. Skipper, J. C., P. H. Gulden, R. C. Hendrickson, N. Harthun, J. A. Caldwell, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1999. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int. J. Cancer 82:669-677.
5. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wolfel, D. Lienard, V. Brichard, et al. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201- restricted Melan-A/ MART-1 antigenic peptide in melanoma. J. Immunol. 159: 2366-2374.
6. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160: 1750-1758.
7. Valmori, D., N. Gervois, D. Rimoldi, J. F. Fonteneau, A. Bonelo, D. Lienard, L. Rivoltini, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. J. Immunol. 161: 6956-6962.
8. Benlalam, H., B. Linard, Y. Guilloux, A. Moreau-Aubry, L. Derre, E. Diez, B. Dreno, F. Jotereau, and N. Labarriere. 2003. Identification of five new HLAB* 3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J. Immunol. 171: 6283-6289.
9. Romero, P., D. Valmori, M. J. Pittet, A. Zippelius, D. Rimoldi, F. Levy, V. Dutoit, M. Ayyoub, V. Rubio-Godoy, O. Michielin, et al. 2002. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol. Rev. 188: 81-96.
10. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180: 347-352.
11. + clones derived from human melanoma-infiltrating lymphocytes. Eur. J. Immunol. 22: 1795-1802.
12. Valmori, D., V. Dutoit, V. Schnuriger, A. L. Quiquerez, M. J. Pittet, P. Guillaume, V. Rubio-Godoy, P. R. Walker, D. Rimoldi, D. Lienard, et al. 2002. Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J. Immunol. 168: 4231-4240.
13. Loftus, D. J., C. Castelli, T. M. Clay, P. Squarcina, F. M. Marincola, M. I. Nishimura, G. Parmiani, E. Appella, and L. Rivoltini. 1996. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J. Exp. Med. 184: 647-657.
14. Sali, A., R. Matsumoto, H. P. McNeil, M. Karplus, and R. L. Stevens. 1993. Three-dimensional models of four mouse mast cell chymases: identification of proteoglycan binding regions and protease-specific antigenic epitopes. J. Biol. Chem. 268: 9023-9034.
15. Fields, B. A., B. Ober, E. L. Malchiodi, M. I. Lebedeva, B. C. Braden, X. Ysern, J. K. Kim, X. Shao, E. S. Ward, and R. A. Mariuzza. 1995. Crystal structure of the Vα domain of a T cell antigen receptor. Science. 270: 1821-1824.
16. Al-Lazikani, B., A. M. Lesk, and C. Chothia. 2000. Canonical structures for the hypervariable regions of T cell αβ receptors. J. Mol. Biol. 295: 979-995.
17. Gohlke, H., C. Kiel, and D. A. Case. 2003. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J. Mol. Biol. 330: 891-913.
18. Zoete, V., and O. Michielin. 2007. Comparison between computational alanine scanning and per-residue binding free energy decomposition for protein-protein association using MM-GBSA: application to the TCR-p-MHC complex. Proteins 67: 1026-1047.
19. Lee, M. S., M. Feig, F. R. Salsbury, Jr., and C. L. Brooks, 3rd. 2003. New analytic approximation to the standard molecular volume definition and its application to generalized Born calculations. J. Comput. Chem. 24: 1348-1356.
20. Lee, M. S., F. R. Salsbury, and C. L. Brooks. 2002. Novel generalized Born methods. J. Chem. Phys. 116: 10606-10614.
21. Brooks, B. R., R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus. 1983. Charmm - a program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4: 187-217.
22. MacKerell, A. D., D. Bashford, M. Bellott, R. L. Dunbrack, J. D. Evanseck, M. J. Field, S. Fischer, J. Gao, H. Guo, S. Ha, et al. 1998. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B. 102: 3586-3616.
23. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180: 35-42.
24. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Appella, et al. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257-2265.
25. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64: 2865-2873.
26. Brinckerhoff, L. H., V. V. Kalashnikov, L. W. Thompson, G. V. Yamshchikov, R. A. Pierce, H. S. Galavotti, V. H. Engelhard, and C. L. Slingluff, Jr. 1999. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int. J. Cancer 83:326-334.
27. Blanchet, J. S., D. Valmori, I. Dufau, M. Ayyoub, C. Nguyen, P. Guillaume, B. Monsarrat, J. C. Cerottini, P. Romero, and J. E. Gairin. 2001. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. J. Immunol. 167: 5852-5861.
28. Valmori, D., F. Levy, I. Miconnet, P. Zajac, G. C. Spagnoli, D. Rimoldi, D. Lienard, V. Cerundolo, J. C. Cerottini, and P. Romero. 2000. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J. Immunol. 164: 1125-1131.
29. Chapatte, L., C. Servis, D. Valmori, O. Burlet-Schiltz, J. Dayer, B. Monsarrat, P. Romero, and F. Levy. 2004. Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLAA* 0201 in melanoma cells. J. Immunol. 173: 6033-6040.
30. Dietrich, P. Y., F. A. Le Gal, V. Dutoit, M. J. Pittet, L. Trautman, A. Zippelius, I. Cognet, V. Widmer, P. R. Walker, O. Michielin, et al. 2003. Prevalent role of TCR α-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J. Immunol. 170: 5103-5109.
31. Dietrich, P. Y., P. R. Walker, A. L. Quiquerez, G. Perrin, V. Dutoit, D. Lienard, P. Guillaume, J. C. Cerottini, P. Romero, and D. Valmori. 2001. Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res. 61: 2047-2054.
32. Trautmann, L., N. Labarriere, F. Jotereau, V. Karanikas, N. Gervois, T. Connerotte, P. Coulie, and M. Bonneville. 2002. Dominant TCR Vα usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur. J. Immunol. 32: 3181-3190.
33. Mantovani, S., B. Palermo, S. Garbelli, R. Campanelli, G. Robustelli Della Cuna, R. Gennari, F. Benvenuto, E. Lantelme, and C. Giachino. 2002. Dominant TCR-α requirements for a self antigen recognition in humans. J. Immunol. 169: 6253-6260.
34. Sensi, M., C. Traversari, M. Radrizzani, S. Salvi, C. Maccalli, R. Mortarini, L. Rivoltini, C. Farina, G. Nicolini, T. Wolfel, et al. 1995. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc. Natl. Acad. Sci. USA 92:5674 -5678.
35. Speiser, D. E., P. Baumgaertner, C. Barbey, V. Rubio-Godoy, A. Moulin, P. Corthesy, E. Devevre, P. Y. Dietrich, D. Rimoldi, D. Lienard, et al. 2006. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J. Immunol. 177: 1338-1348.
36. Itoh, K., C. D. Platsoucas, and C. M. Balch. 1988. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J. Exp. Med. 168: 1419-1441.
37. Topalian, S. L., D. Solomon, and S. A. Rosenberg. 1989. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142: 3714-3725.
38. Boon, T., P. G. Coulie, B. J. Van den Eynde, and P. van der Bruggen. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
39. Schneider, J., V. Brichard, T. Boon, K. H. Meyer zum Buschenfelde, and T. Wolfel. 1998. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int. J. Cancer 75: 451-458.
40. Sliz, P., O. Michielin, J. C. Cerottini, I. Luescher, P. Romero, M. Karplus, and D. C. Wiley. 2001. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J. Immunol. 167: 3276-3284.
41. Khan, A. R., B. M. Baker, P. Ghosh, W. E. Biddison, and D. C. Wiley. 2000. The structure and stability of an HLA-A*0201/octameric tax peptide complex with an empty conserved peptide-N-terminal binding site. J. Immunol. 164: 6398-6405.
42. Zippelius, A., M. J. Pittet, P. Batard, N. Rufer, M. de Smedt, P. Guillaume, K. Ellefsen, D. Valmori, D. Lienard, J. Plum, et al. 2002. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med. 195: 485-494.
43. + T cells in humans. J. Exp. Med. 196: 207-216.
44. Pittet, M. J., A. Gati, F. A. Le Gal, G. Bioley, P. Guillaume, M. de Smedt, J. Plum, D. E. Speiser, J. C. Cerottini, P. Y. Dietrich, et al. 2006. Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J. Immunol. 176: 2330-2336.
45. Speiser, D. E., M. J. Pittet, D. Rimoldi, P. Guillaume, I. F. Luescher, D. Lienard, F. Lejeune, J. C. Cerottini, and P. Romero. 2003. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin. Cancer Biol. 13: 461-472.
46. Wang, F., E. Bade, C. Kuniyoshi, L. Spears, G. Jeffery, V. Marty, S. Groshen, and J. Weber. 1999. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res. 5: 2756-2765.
47. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115: 739-746.
48. + T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res. 63: 1560-1567.